|
|
We Have Recently Made Changes to Our Website, If you are unable to find something Specific, Please Search Below
Publish Date : 9/10/2004 1:48:00 PM Source : SkinCareIndia Health News From mollusks to mammals, newly discovered chemical pathways of serotonin in the nervous system are paving a path toward future pharmaceutical treatments for depression and other disorders.
"Understanding novel serotonin pathways in a tissue-dependent manner is useful for the development of pharmaceuticals intended to preserve serotonergic signaling," said Jeffrey N. Stuart, a doctoral student in the department of chemistry at the University of Illinois at Urbana-Champaign. Recent findings by Stuart and his Illinois colleagues were the topic of a talk, "Characterization of Novel Serotonin Biochemical Pathways for Potential Therapeutic Applications," last month at the American Chemical Society's 228th National Meeting in Philadelphia and of a paper in the August issue of the Journal of Neurochemistry. Serotonin (5-hydroxytryptamine, or 5-HT) is a neurotransmitter present throughout the body. When nerve cells containing it are activated, serotonin is released. It travels and stimulates other nerve cells, enabling their message to spread through the nervous system. "When serotonin is released, you do not want its signal to last forever," said Jonathan Sweedler, professor of chemistry and Stuart's academic adviser. The signal caused by serotonin is turned off by enzymes that inactivate it by converting it into various metabolites, such as the ones discovered by Stuart. Disruptions of serotonin signaling pathways are thought to occur in disorders such as depression, anxiety, sudden infant death syndrome, attention deficit hyperactivity disorder and irritable bowel syndrome. Many pharmaceutical treatments restore the pathways by preventing the cellular uptake of serotonin, where it is converted to other metabolites, or by directly inhibiting the enzymes responsible for the molecular conversion. Because serotonin is distributed throughout the body, pharmaceuticals intended to correct serotonin imbalances in a specific tissue, such as in the brain, ultimately take effect in other tissues as well. That potentially leads to unwanted side effects. Stuart, using a detection system built to measure serotonin and related compounds, found two new serotonin metabolites in the nervous system of marine mollusks. The metabolites were in separate yet adjacent body tissues, suggesting, he said, that different chemical pathways exist to convert serotonin. "Characterization of site-specific serotonin pathways could provide novel means by which to more precisely target tissue-specific diseases related to 5-HT, such as in the brain or enteric nervous system," he said. "Because enzymes exist in mammals that can convert serotonin into metabolites, future treatments of nervous system disorders could exploit these pathways so that only a specific pathway in a specific tissue is affected." Marine mollusks, such as the species Aplysia californica and Pleurobranchaea californica that were used in these experiments, are considered to be ideal model systems to study serotonin processing because they have simpler nervous systems than mammals. "They have larger, more easily identified neurons," Stuart said. Mollusks are also good model systems because they show some mammal-like qualities that influence behavior, such as learning and memory, a discovery for which the Nobel Prize in Physiology or Medicine was awarded in 2000 to Eric Kandel of Columbia University in New York. Kandel studied how learning behavior was related to serotonergic and other signaling pathways in Aplysia californica, which are sea slugs the color of a purple plum that range up to a melon in size. Aplysia californica live in warm, shallow water off the California coast in areas rich in vegetation where they feed on algae. Pleurobranchaea californica live in the cold, dark depths of the ocean floor, "and each one resembles a wet brown paper bag with the appetite and table manners of a hyena," said Rhanor Gillette, a professor in the department of molecular and integrative physiology at Illinois. He collaborated with Stuart and Sweedler to study how serotonin metabolites relate to behavior. As predators, Pleurobranchaea feed voraciously on marine animals, including other Pleurobranchaea, ocean-bottom dwelling invertebrates and some fish. The Pleurobranchaea used in the Illinois research are captured in trawl nets off the southern California coast. Like Aplysia, Pleurobranchaea also display learning and memory behaviors influenced by serotonin. "Serotonin is a major factor in organizing the behavior of Pleurobranchaea, particularly for feeding," Gillette said. "Some potential prey have dangerous, stinging defenses. In a single encounter, Pleurobranchaea learn to avoid their odor, Pleurobranchaea learn to avoid it by doing a characteristic avoidance turn during subsequent encounters. We are working with the serotonin pathways that underlie the odor learning." Stuart reported at the ACS meeting that hungry Pleurobranchaea had more serotonin sulfate, one of the newly discovered serotonin metabolites, which could indicate that serotonin sulfate is a signal for hunger. Stuart and Jason Ebaugh, a doctoral student in the neuroscience program, measured the blood levels of serotonin sulfate as a time-of-day function. It may be important for growth, most of which occurs during sleep, Gillette said. It's possible that the role of serotonin sulfate in marine mollusks is similar to melatonin, which resests the circadian clock in humans, Stuart and colleagues suggested in the Journal of Neurochemistry. "This is the first quantitative measure of how serotonin metabolites are related to a behavioral state in marine mollusks," Sweedler said. "What we do not know is whether serotonin sulfate causes the behavior or whether the behavior causes the elevation of serotonin sulfate." Other contributors to the research are Leah Squires, Elena Romanova, Jennifer Jakubowski and Xin Zhang, all doctoral students in the department of chemistry; postdoctoral fellows Stanislav Rubakhin and Nathan Hatcher, both in chemistry; and undergraduate biochemistry major Ashley Copes. The National Institutes of Health funded the research. Stuart also was supported by an ACS fellowship. |
|
Cervical cancer vaccine breakthrough
Publish Date : 11/15/2004 1:16:00 PM Scientists say they have tested a vaccine, Cervarix, that protects women from two strains of HPV (human papillomavirus) which are responsible for 70% of cervical cancers. Beyond Tactical Struggles over Public Policy -The President's Council on Bioethics Publish Date : 11/15/2004 1:15:00 PM An on-stage discussion with William F May, PhD. Bioethicist and Author Human mad cow disease, there are many different forms of it Publish Date : 11/15/2004 1:15:00 PM Depending on your genetic makeup, vCJD (Varian Mad Cow Disease) will manifest itself differently, say researchers. This means vCJD may be present in some areas without being detected (vCJD means the human form of mad cow disease). New online tool kit on HIV/AIDS prevention for sex workers Publish Date : 11/15/2004 1:11:00 PM GTZ, WHO and sex work networks share information and lessons learned - The German technical cooperation (GTZ) and the World Health Organization (WHO), in collaboration with sex work networks around the world..... Anti-drug driving campaign wins award Publish Date : 11/10/2004 7:34:00 PM A road safety initiative to stop people driving under the influence of drugs has won an award at the THINK road safety conference. Text Messaging Helps Patients in Developing Countries Manage HIV/AIDS Treatment Publish Date : 11/10/2004 7:33:00 PM Wired News on Thursday examined how HIV/AIDS treatment counselors in countries where health care .... Roche Diagnostics Launches Highly-sensitive Polymerase Chain Reaction System Publish Date : 11/10/2004 7:32:00 PM Roche Diagnositcs has begun sales of it's real-time polymerase chain reaction (PCR) system LightCycler ST300, a highly-sensitive gene analysis system. 3 by 5 Initiative for HIV 'Probably Will Not' Meet Treatment Publish Date : 11/10/2004 7:31:00 PM The World Health Organization's 3 by 5 Initiative goal of treating three million HIV-positive people with antiretroviral ........ Manufacturing Approval for Statmark Influenza Virus Detection Reagent Publish Date : 11/10/2004 7:30:00 PM Nichirei (TSe: 2871), a leading Japanese food processing company, has announced that it has ..... US Health Improvements Slowing - Alarm at High Infant Mortality Rates and Obesity Publish Date : 11/10/2004 7:28:00 PM Although the overall health of US residents continues to improve, health indicators show that ... Total Results : 3044 More News (Opens in New Window) : [1] 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 Next Page |
|